Addendum
Atezolizumab (non-small cell lung cancer) – Addendum to Commission A17-50
Report documents
-
Addendum
Atezolizumab (non-small cell lung cancer) – Addendum to Commission A17-50
Dossier assessment
Indication:
Adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy
Result of dossier assessment:
No change in the conclusion compared with the dossier assessment A17-50
Additional information
Federal Joint Committee (G-BA)
2018-03-16 A G-BA decision was published.
Project details
- Project no.
- A18-09
- Commission
- Commission awarded on 05.02.2018 by the Federal Joint Committee (GBA).
- Report type
- Addendum
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Cancer
- Note
-
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
Connected Projects
-
Dossier assessment
Atezolizumab (small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Atezolizumab (non-small cell lung cancer) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed